# Clinical Trial Landscape: 07_pancreatic_kras_g12d

*Generated: 2026-01-05 06:58:11*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 12

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 1 | 34 | ██████ 34.0% |
| Phase 1/Phase 2 | 20 | ████ 20.0% |
| Phase 2 | 17 | ███ 17.0% |
| Unknown | 14 | ██ 14.0% |
| Not Applicable | 7 | █ 7.0% |
| Phase 3 | 4 |  4.0% |
| Early Phase 1 | 2 |  2.0% |
| Phase 4 | 1 |  1.0% |
| Phase 2/Phase 3 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 94 (94.0%)
- **Not yet recruiting**: 4 (4.0%)
- **Enrolling by invitation**: 2 (2.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| M.D. Anderson Cancer Center | 6 |
| National Cancer Institute (NCI) | 4 |
| Revolution Medicines, Inc. | 4 |
| Eli Lilly and Company | 4 |
| Sidney Kimmel Comprehensive Cancer Center at Johns | 3 |
| Astellas Pharma Inc | 3 |
| University of California, San Francisco | 2 |
| AbbVie | 2 |
| Dana-Farber Cancer Institute | 2 |
| H. Lee Moffitt Cancer Center and Research Institut | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Genentech, Inc. | 2 |
| AstraZeneca | 2 |
| Roswell Park Cancer Institute | 2 |
| Abramson Cancer Center at Penn Medicine | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Gemcitabine | 10 |
| Cetuximab | 10 |
| Oxaliplatin | 7 |
| Pembrolizumab | 7 |
| Health Telemonitoring | 6 |
| Biospecimen Collection | 6 |
| Computed Tomography | 6 |
| Irinotecan | 6 |
| Leucovorin | 5 |
| Nab-paclitaxel | 4 |
| RMC-6236 | 4 |
| Fluorouracil | 4 |
| Cisplatin | 4 |
| Carboplatin | 4 |
| Pemetrexed | 4 |
| TSN1611 | 4 |
| Questionnaire Administration | 3 |
| Nivolumab | 3 |
| Magnetic Resonance Imaging | 3 |
| Positron Emission Tomography | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Spain | 15 |
| South Korea | 12 |
| Canada | 11 |
| France | 11 |
| Australia | 9 |
| Italy | 8 |
| Japan | 8 |
| Germany | 6 |
| Taiwan | 6 |
| Israel | 5 |
| United Kingdom | 5 |
| Belgium | 5 |
| China | 5 |
| Netherlands | 4 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12D | manual | 1.0 |
| KRASG12D | manual | 0.9 |
| KRAS-G12D | manual | 0.9 |
| pancreatic cancer | manual | 1.0 |
| KRAS G12D pancreatic cancer | manual | 1.0 |
| KRAS G12D pancreatic ductal adenocarcinoma | llm | 0.9 |
| pancreatic cancer KRAS G12D | llm | 0.9 |
| pancreatic ductal adenocarcinoma | llm | 0.8 |
| PDAC | llm | 0.8 |
| KRAS p.G12D | llm | 0.9 |
| KRASp.G12D | llm | 0.8 |
| KRAS-p.G12D | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07217717](https://clinicaltrials.gov/study/NCT07217717) | Phase 3 | Recruiting | SOFIE | A Phase 3, Multicenter, Prospective... |
| [NCT06821997](https://clinicaltrials.gov/study/NCT06821997) | Phase 2 | Recruiting | Roswell Park Cancer ... | A Phase 2 Clinical Trial of Nalirif... |
| [NCT07033689](https://clinicaltrials.gov/study/NCT07033689) | Early Phase 1 | Not yet recruiting | SONIRE Therapeutics ... | Open-label, Non-randomized, Single-... |
| [NCT07214298](https://clinicaltrials.gov/study/NCT07214298) | Phase 1/Phase 2 | Not yet recruiting | Roswell Park Cancer ... | A Phase I/II Study of Complement In... |
| [NCT07223047](https://clinicaltrials.gov/study/NCT07223047) | Phase 1/Phase 2 | Recruiting | Bristol-Myers Squibb | A Phase 1/2a, Open-Label, Multicent... |
| [NCT07186842](https://clinicaltrials.gov/study/NCT07186842) | Phase 1/Phase 2 | Recruiting | BioNTech SE | First-in-human, Open-label, Multi-s... |
| [NCT06790602](https://clinicaltrials.gov/study/NCT06790602) | Phase 2 | Not yet recruiting | University of Califo... | A Single-arm, Open-label, Phase II ... |
| [NCT07213791](https://clinicaltrials.gov/study/NCT07213791) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Dose Escalation and Dose Optimiza... |
| [NCT04119024](https://clinicaltrials.gov/study/NCT04119024) | Phase 1 | Recruiting | Anusha Kalbasi | Phase I Dose Escalation Study of Sy... |
| [NCT07043270](https://clinicaltrials.gov/study/NCT07043270) | Phase 2 | Recruiting | Dartmouth-Hitchcock ... | 24BRO681 : Neoadjuvant Therapy With... |
| [NCT07207707](https://clinicaltrials.gov/study/NCT07207707) | Phase 1 | Recruiting | Kumquat Biosciences ... | A Phase 1a, Open-label, Multicenter... |
| [NCT06503146](https://clinicaltrials.gov/study/NCT06503146) | Phase 2 | Recruiting | National Cancer Inst... | 18F-Fibroblast Activation Protein I... |
| [NCT06941857](https://clinicaltrials.gov/study/NCT06941857) | Phase 2 | Recruiting | Sidney Kimmel Compre... | A Phase 2 Study of NC410 and FOLFIR... |
| [NCT06984562](https://clinicaltrials.gov/study/NCT06984562) | Not Applicable | Recruiting | Fox Chase Cancer Cen... | Adaptive Radiation for Locally Adva... |
| [NCT07118176](https://clinicaltrials.gov/study/NCT07118176) | Phase 1 | Recruiting | Jonsson Comprehensiv... | PET Imaging Study of 68Ga-FAPI-46 B... |
| [NCT07021066](https://clinicaltrials.gov/study/NCT07021066) | Phase 1 | Recruiting | SystImmune Inc. | A Phase 1 Open-Label Study to Evalu... |
| [NCT07094204](https://clinicaltrials.gov/study/NCT07094204) | Phase 1 | Recruiting | Astellas Pharma Inc | A Phase 1 Study of ASP5834 in Parti... |
| [NCT06411691](https://clinicaltrials.gov/study/NCT06411691) | Phase 1 | Recruiting | Sidney Kimmel Compre... | Pooled Mutant KRAS-Targeted Long Pe... |
| [NCT07020221](https://clinicaltrials.gov/study/NCT07020221) | Phase 1/Phase 2 | Recruiting | Verastem, Inc. | A Phase 1/2a, Open-label Study of V... |
| [NCT06850623](https://clinicaltrials.gov/study/NCT06850623) | Phase 2 | Recruiting | EXACT Therapeutics A... | A Phase 2 Study to Investigate the ... |
| [NCT06843551](https://clinicaltrials.gov/study/NCT06843551) | Phase 2 | Recruiting | Benjamin Spieler | A Phase 2 Single Arm Trial of Stere... |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Phase 1/Phase 2 | Recruiting | Arvinas Inc. | A Phase 1/2 Clinical Trial to Evalu... |
| [NCT06648434](https://clinicaltrials.gov/study/NCT06648434) | Phase 1 | Recruiting | Washington Universit... | Phase I Trial of MK2 Inhibitor in C... |
| [NCT06937996](https://clinicaltrials.gov/study/NCT06937996) | N/A | Recruiting | Englewood Hospital a... | Outcomes of Ablation of Unresectabl... |
| [NCT06807437](https://clinicaltrials.gov/study/NCT06807437) | Phase 3 | Recruiting | SWOG Cancer Research... | A Randomized Phase III Blinded Tria... |
| [NCT06710756](https://clinicaltrials.gov/study/NCT06710756) | Phase 1/Phase 2 | Recruiting | Perspective Therapeu... | A Phase I/IIa Image-Guided, Alpha-P... |
| [NCT06917079](https://clinicaltrials.gov/study/NCT06917079) | Phase 1 | Recruiting | TheRas, Inc., d/b/a ... | A Phase 1a/1b Open-Label Study Eval... |
| [NCT06712797](https://clinicaltrials.gov/study/NCT06712797) | Not Applicable | Recruiting | H. Lee Moffitt Cance... | Physical Activity and Nutrition to ... |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Phase 2 | Recruiting | Jazz Pharmaceuticals | A Phase 2, Open-label, Multicenter ... |
| [NCT06797336](https://clinicaltrials.gov/study/NCT06797336) | Phase 1 | Recruiting | PAQ Therapeutics, In... | A Phase 1, Open-Label Dose Escalati... |
| [NCT06619587](https://clinicaltrials.gov/study/NCT06619587) | Phase 1 | Recruiting | Genentech, Inc. | A Phase I/II Dose-Escalation and Ex... |
| [NCT07174609](https://clinicaltrials.gov/study/NCT07174609) | Not Applicable | Recruiting | Johns Hopkins Univer... | A Pilot Study of Scrambler Therapy ... |
| [NCT06593431](https://clinicaltrials.gov/study/NCT06593431) | Phase 3 | Recruiting | M.D. Anderson Cancer... | Extending Outcomes for Pancreas Can... |
| [NCT06607185](https://clinicaltrials.gov/study/NCT06607185) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Study of the Pan-KRAS... |
| [NCT06600906](https://clinicaltrials.gov/study/NCT06600906) | N/A | Recruiting | University of Califo... | Translating Hyperpolarized 13C MRI ... |
| [NCT06598007](https://clinicaltrials.gov/study/NCT06598007) | Phase 1/Phase 2 | Recruiting | Crossignal Therapeut... | A Phase 1/2a First-In-Human, Open-L... |
| [NCT06586515](https://clinicaltrials.gov/study/NCT06586515) | Phase 1 | Recruiting | Eli Lilly and Compan... | A Phase 1a/1b Trial of LY3962673 in... |
| [NCT06582017](https://clinicaltrials.gov/study/NCT06582017) | Phase 1 | Recruiting | Nammi Therapeutics I... | A First-in-human Phase 1a/1b Study ... |
| [NCT06447662](https://clinicaltrials.gov/study/NCT06447662) | Phase 1 | Recruiting | Pfizer | A Phase 1 Open-Label Study of PF-07... |
| [NCT07224750](https://clinicaltrials.gov/study/NCT07224750) | N/A | Recruiting | City of Hope Medical... | A Noninvasive and Screening miRNA S... |
| [NCT06539169](https://clinicaltrials.gov/study/NCT06539169) | N/A | Recruiting | xCures | FLOWER: Following Longitudinal Outc... |
| [NCT06445062](https://clinicaltrials.gov/study/NCT06445062) | Phase 1/Phase 2 | Recruiting | Revolution Medicines... | A Platform Study of RAS(ON) Inhibit... |
| [NCT06400472](https://clinicaltrials.gov/study/NCT06400472) | Phase 1 | Recruiting | Eli Lilly and Compan... | A First-in-Human, Phase 1a/1b Trial... |
| [NCT05919238](https://clinicaltrials.gov/study/NCT05919238) | Phase 1 | Recruiting | Impact Biotech Ltd | A Multicenter Open-label Phase 1 Tr... |
| [NCT06385925](https://clinicaltrials.gov/study/NCT06385925) | Phase 1/Phase 2 | Recruiting | Tyligand Pharmaceuti... | Phase 1/2 Study of TSN1611 in Subje... |
| [NCT06364696](https://clinicaltrials.gov/study/NCT06364696) | Phase 1 | Recruiting | Astellas Pharma Inc | An Open-label Phase 1 Study of ASP4... |
| [NCT06218914](https://clinicaltrials.gov/study/NCT06218914) | Phase 1 | Recruiting | AstraZeneca | Open-label, Phase 1, Multi-Center M... |
| [NCT06233877](https://clinicaltrials.gov/study/NCT06233877) | Phase 2 | Not yet recruiting | Hirschfeld Oncology | An Open Label Phase 2 Trial to Eval... |
| [NCT06227377](https://clinicaltrials.gov/study/NCT06227377) | Phase 1 | Recruiting | Quanta Therapeutics | A Phase 1 Trial Evaluating the Safe... |
| [NCT06157671](https://clinicaltrials.gov/study/NCT06157671) | N/A | Enrolling by invitation | Adenocyte, LLC | The LINFU® (A Noninvasive Method fo... |

*... and 50 more trials (see trials.csv for full list)*
